Santen Pharmaceutical
(OTC) SNPHY
Santen Pharmaceutical Financials at a Glance
Market Cap
$3.50B
Revenue (TTM)
$290.51B
Net Income (TTM)
$30.89B
EPS (TTM)
$0.61
P/E Ratio
17.74
Dividend
$0.25
Beta (Volatility)
0.29 (Low)
Dividend
$0.25
Beta (Volatility)
0.29 (Low)
Price
$10.73
Volume
2,495
Open
$11.00
Price
$10.73
Volume
2,495
Open
$11.00
Previous Close
$10.73
Daily Range
$10.65 - $11.00
52-Week Range
$8.89 - $12.04
Dividend
$0.25
Beta (Volatility)
0.29 (Low)
Price
$10.73
Volume
2,495
Open
$11.00
Previous Close
$10.73
Daily Range
$10.65 - $11.00
52-Week Range
$8.89 - $12.04
SNPHY News
SNPHY: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Santen Pharmaceutical
Industry
Pharmaceuticals
Sector
Health CareEmployees
3,849
CEO
Takeshi Ito
Website
www.santen.co.jpHeadquarters
Osaka, 530-8552, JP
SNPHY Financials
Key Financial Metrics (TTM)
Gross Margin
54%
Operating Margin
14%
Net Income Margin
11%
Return on Equity
11%
Return on Capital
13%
Return on Assets
8%
Earnings Yield
5.64%
Dividend Yield
0.02%
Payout Ratio
41.30%
Stock Overview
Market Cap
$3.50B
Shares Outstanding
321.67M
Volume
2.50K
Short Interest
0.00%
Avg. Volume
12.47K
Financials (TTM)
Gross Profit
$171.03B
Operating Income
$46.88B
EBITDA
$59.01B
Operating Cash Flow
$60.93B
Capital Expenditure
$6.66B
Free Cash Flow
$54.27B
Cash & ST Invst.
$93.99B
Total Debt
$34.23B
Santen Pharmaceutical Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$74.20B
-2.8%
Gross Profit
$39.24B
-7.1%
Gross Margin
52.88%
N/A
Market Cap
$3.50B
N/A
Market Cap/Employee
$933.91K
N/A
Employees
3,744
N/A
Net Income
$8.02B
-7.8%
EBITDA
$15.65B
-1.1%
Quarterly Fundamentals
Net Cash
$25.42B
-67.4%
Accounts Receivable
$69.40B
+0.5%
Inventory
$60.11B
+20.2%
Long Term Debt
$36.17B
N/A
Short Term Debt
$0.00
N/A
Return on Assets
7.63%
N/A
Return on Invested Capital
12.68%
N/A
Free Cash Flow
$7.65B
-28.3%
Operating Cash Flow
$9.25B
-32.6%